Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000265433 | SCV000343336 | uncertain significance | not provided | 2016-07-12 | criteria provided, single submitter | clinical testing | |
Invitae | RCV000265433 | SCV002132787 | pathogenic | not provided | 2024-01-03 | criteria provided, single submitter | clinical testing | This sequence change replaces isoleucine, which is neutral and non-polar, with threonine, which is neutral and polar, at codon 571 of the CNGA3 protein (p.Ile571Thr). This variant is present in population databases (rs750456621, gnomAD 0.002%). This missense change has been observed in individual(s) with CNGA3-related conditions (PMID: 32869108). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 289061). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt CNGA3 protein function with a positive predictive value of 80%. This variant disrupts the p.Ile571 amino acid residue in CNGA3. Other variant(s) that disrupt this residue have been determined to be pathogenic (Invitae). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. |